Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10697) 10697
Magazine Article (21) 21
Book Chapter (9) 9
Publication (8) 8
Conference Proceeding (7) 7
Dissertation (5) 5
Book / eBook (2) 2
Newsletter (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (10485) 10485
humans (10385) 10385
science & technology (8542) 8542
life sciences & biomedicine (8435) 8435
middle aged (7969) 7969
postmenopause (6874) 6874
aged (5022) 5022
biological and medical sciences (4225) 4225
medical sciences (3829) 3829
postmenopausal women (2760) 2760
menopause (2542) 2542
adult (2389) 2389
obstetrics & gynecology (2345) 2345
risk factors (1973) 1973
pharmacology. drug treatments (1947) 1947
postmenopause - drug effects (1741) 1741
estrogen replacement therapy (1665) 1665
breast neoplasms - drug therapy (1663) 1663
hormone replacement therapy (1566) 1566
double-blind method (1559) 1559
endocrinology & metabolism (1545) 1545
oncology (1535) 1535
breast cancer (1521) 1521
abridged index medicus (1491) 1491
postmenopause - physiology (1396) 1396
treatment outcome (1366) 1366
health aspects (1351) 1351
women (1245) 1245
postmenopause - blood (1108) 1108
estrogen (1102) 1102
aged, 80 and over (1089) 1089
osteoporosis (1070) 1070
gynecology. andrology. obstetrics (1054) 1054
prospective studies (1021) 1021
hormone therapy (895) 895
hormones. endocrine system (854) 854
estradiol - administration & dosage (816) 816
bone density - drug effects (809) 809
medicine & public health (806) 806
research (806) 806
analysis (771) 771
tumors (766) 766
estrogen replacement therapy - adverse effects (763) 763
time factors (755) 755
bone density (729) 729
estrogens (729) 729
womens health (725) 725
fundamental and applied biological sciences. psychology (721) 721
breast neoplasms - pathology (718) 718
tamoxifen - therapeutic use (715) 715
follow-up studies (704) 704
general & internal medicine (700) 700
medicine, general & internal (695) 695
postmenopause - metabolism (681) 681
body mass index (679) 679
geriatrics & gerontology (650) 650
antineoplastic agents, hormonal - therapeutic use (647) 647
animals (638) 638
male (599) 599
care and treatment (593) 593
cancer (587) 587
dose-response relationship, drug (581) 581
cardiovascular system & cardiology (567) 567
administration, oral (565) 565
tamoxifen (558) 558
hormones (553) 553
cross-sectional studies (547) 547
case-control studies (528) 528
surveys and questionnaires (528) 528
internal medicine (521) 521
drug therapy (517) 517
estrogen replacement therapy - methods (515) 515
physiological aspects (515) 515
post-menopause (509) 509
mammary gland diseases (508) 508
estradiol - blood (505) 505
estradiol - pharmacology (489) 489
bones (487) 487
randomized controlled trials as topic (486) 486
quality of life (484) 484
premenopause (481) 481
women's health (478) 478
pharmacology & pharmacy (474) 474
estradiol - therapeutic use (473) 473
clinical trials (462) 462
cohort studies (462) 462
estrogens - therapeutic use (458) 458
chemotherapy, adjuvant (455) 455
drug therapy, combination (455) 455
administration, cutaneous (453) 453
age factors (444) 444
biomarkers - blood (441) 441
bone mineral density (441) 441
lipids - blood (436) 436
nutrition & dietetics (436) 436
drug administration schedule (434) 434
estrogens - administration & dosage (428) 428
aromatase inhibitors - therapeutic use (423) 423
estradiol (416) 416
cross-over studies (412) 412
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10467) 10467
French (61) 61
Spanish (57) 57
German (49) 49
Japanese (49) 49
Russian (49) 49
Chinese (46) 46
Polish (45) 45
Portuguese (34) 34
Italian (23) 23
Bulgarian (15) 15
Hungarian (11) 11
Danish (7) 7
Serbian (5) 5
Swedish (5) 5
Dutch (4) 4
Norwegian (4) 4
Turkish (4) 4
Croatian (3) 3
Czech (3) 3
Korean (3) 3
Finnish (2) 2
Hebrew (2) 2
Persian (1) 1
Romanian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
by Stephen Johnston and John Pippen, Jr and Xavier Pivot and Mikhail Lichinitser and Saeed Sadeghi and Veronique Dieras and Henry Leonidas Gomez and Gilles Romieu and Alexey Manikhas and M. John Kennedy and Michael F. Press and Julie Maltzman and Allison Florance and Lisa O'Rourke and Cristina Oliva and Steven Stein and Mark Pegram
Journal of clinical oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Life Sciences & Biomedicine | Oncology | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy
by Kendler, David L and Roux, Christian and Benhamou, Claude Laurent and Brown, Jacques P and Lillestol, Michael and Siddhanti, Suresh and Man, Hoi‐Shen and Martin, Javier San and Bone, Henry G
Journal of bone and mineral research, ISSN 0884-0431, 01/2010, Volume 25, Issue 1, pp. 72 - 81
clinical trial | bone mineral density | RANKL | alendronate | denosumab | postmenopausal osteoporosis | Clinical trial | Bone mineral density | Alendronate | Denosumab | Postmenopausal osteoporosis | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Collagen Type I - blood | Peptides - blood | Postmenopause - blood | Postmenopause - drug effects | Demography | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Bone Remodeling - drug effects | Alendronate - therapeutic use | Antibodies, Monoclonal, Humanized | RANK Ligand - pharmacology | Peptide Fragments - blood | Female | RANK Ligand - adverse effects | Bone Density Conservation Agents - adverse effects | Antibodies, Monoclonal - pharmacology | Lumbar Vertebrae - drug effects | Procollagen - blood | Biomarkers - blood | Hip | Bone Density Conservation Agents - pharmacology | Alendronate - adverse effects | Bone Density - drug effects | Alendronate - pharmacology | Aged | Femur Neck - drug effects | Osteoporosis | Bone density | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Effects of Continuing or Stopping Alendronate After 5 Years of Treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A Randomized Trial
by Black, Dennis M and Schwartz, Ann V and Ensrud, Kristine E and Cauley, Jane A and Levis, Silvina and Quandt, Sara A and Satterfield, Suzanne and Wallace, Robert B and Bauer, Douglas C and Palermo, Lisa and Wehren, Lois E and Lombardi, Antonio and Santora, Arthur C and Cummings, Steven R and FLEX Research Group, for the and FLEX Res Grp and FLEX Research Group
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 12/2006, Volume 296, Issue 24, pp. 2927 - 2938
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Medical sciences | Double-Blind Method | Follow-Up Studies | Humans | Spinal Fractures - epidemiology | Bone Density Conservation Agents - therapeutic use | Fractures, Bone - epidemiology | Risk | Bone Remodeling - physiology | Biomarkers - blood | Bone Density Conservation Agents - administration & dosage | Bone Remodeling - drug effects | Osteoporosis, Postmenopausal - drug therapy | Alendronate - therapeutic use | Bone Density - drug effects | Time Factors | Biopsy | Ilium - pathology | Postmenopause | Female | Aged | Fractures, Bone - prevention & control | Alendronate - administration & dosage | Care and treatment | Usage | Fractures | Alendronate | Postmenopausal women | Health aspects | Risk factors | Women | Osteoporosis | Risk assessment | Clinical trials | Bone density | Drug therapy | Long term | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Black cohosh (Cimicifuga spp.) for menopausal symptoms
by Leach, Matthew J and Moore, Vivienne and Leach, Matthew J
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 2012, Volume 2012, Issue 10, pp. CD007244 - CD007244
Sweating | Menopause | PREVENTION AND TREATMENT OF LONG TERM PROBLEMS | Dehydration | Trifolium | CLIMACTERIC/MENOPAUSE | Randomized Controlled Trials as Topic | Gynaecology | Cimicifuga | Complementary & alternative medicine | Hot Flashes | Vaginal Diseases | Postmenopause | Perimenopause | Phytotherapy | Medicine General & Introductory Medical Sciences | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hot Flashes - drug therapy | Postmenopause - drug effects | Humans | Middle Aged | Perimenopause - drug effects | Cimicifuga - adverse effects | Sweating - drug effects | Phytotherapy - adverse effects | Female | Dehydration - drug therapy | Phytotherapy - methods | Vaginal Diseases - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
by Coleman, R and de Boer, R and Eidtmann, H and Llombart, A and Davidson, N and Neven, P and von Minckwitz, G and Sleeboom, H.P and Forbes, J and Barrios, C and Frassoldati, A and Campbell, I and Paija, O and Martin, N and Modi, A and Bundred, N
Annals of oncology, ISSN 0923-7534, 02/2013, Volume 24, Issue 2, pp. 398 - 405
breast cancer | zoledronic acid | anticancer | bone loss | survival | aromatase inhibitor | Zoledronic acid | Breast cancer | Aromatase inhibitor | Anticancer | Bone loss | Survival | Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Pharmacology. Drug treatments | Bones, joints and connective tissue. Antiinflammatory agents | Triazoles - adverse effects | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Breast Neoplasms - physiopathology | Aromatase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Diphosphonates - therapeutic use | Postmenopause | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Aromatase Inhibitors - therapeutic use | Diphosphonates - adverse effects | Triazoles - therapeutic use | Lumbar Vertebrae - metabolism | Bone Density Conservation Agents - adverse effects | Drug Administration Schedule | Imidazoles - adverse effects | Bone Density Conservation Agents - therapeutic use | Lumbar Vertebrae - drug effects | Zoledronic Acid | Breast Neoplasms - drug therapy | Disease-Free Survival | Bone Density - drug effects | Aged | Nitriles - adverse effects | Letrozole | Nitriles - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: A randomized trial
by Marini, Herbert and Minutoli, Letteria and Polito, Francesca and Bitto, Alessandra and Altavilla, Domenica and Atteritano, Marco and Gaudio, Agostino and Mazzaferro, Susanna and Frisina, Alessia and Frisina, Nicola and Lubrano, Carla and Bonaiuto, Michele and D'Anna, Rosario and Cannata, Maria Letizia and Corrado, Francesco and Adamo, Elena Bianca and Wilson, Steven and Squadrito, Francesco
Annals of internal medicine, ISSN 0003-4819, 06/2007, Volume 146, Issue 12, pp. 839 - 847
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Osteoporosis. Osteomalacia. Paget disease | Biological and medical sciences | General aspects | Medical sciences | Diseases of the osteoarticular system | Double-Blind Method | Humans | Middle Aged | Endometrium - drug effects | Bone Diseases, Metabolic - drug therapy | Bone Diseases, Metabolic - metabolism | Bone Density - drug effects | Postmenopause - metabolism | Bone and Bones - metabolism | Genistein - pharmacology | Female | Aged | Genistein - adverse effects | Osteoporosis | Postmenopausal women | Drug therapy | Health aspects | Isoflavones | Women | Phytochemicals | Older people | Clinical trials | Bone density | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol
by Hodis, Howard N and Mack, Wendy J and Henderson, Victor W and Shoupe, Donna and Budoff, Matthew J and Hwang-Levine, Juliana and Li, Yanjie and Feng, Mei and Dustin, Laurie and Kono, Naoko and Stanczyk, Frank Z and Selzer, Robert H and Azen, Stanley P and Elite Res Grp and ELITE Research Group
The New England journal of medicine, ISSN 0028-4793, 03/2016, Volume 374, Issue 13, pp. 1221 - 1231
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Carotid Arteries - drug effects | Estrogen Replacement Therapy | Postmenopause - drug effects | Drug Administration Schedule | Administration, Oral | Carotid Intima-Media Thickness | Progesterone - administration & dosage | Humans | Middle Aged | Coronary Artery Disease - prevention & control | Estradiol - administration & dosage | Administration, Intravaginal | Linear Models | Disease Progression | Female | Carotid Arteries - pathology | Atherosclerosis - prevention & control | Atherosclerosis | Estrogen | Dosage and administration | Postmenopausal women | Research | Estradiol | Health aspects | Risk factors | Heart | Calcium | Menopause | Estrogens | Coronary artery | Vagina | Stenosis | 17β-Estradiol | Clinical outcomes | Post-menopause | Computed tomography | Uterus | Womens health | Arteriosclerosis | Aging | Hormone replacement therapy | Progesterone | Carotid artery | Cardiovascular diseases | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Differing effects of PTH 1–34, PTH 1–84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: An 18‐month open‐labeled observational study using HR‐pQCT
by Hansen, Stinus and Hauge, Ellen M and Beck Jensen, Jens‐Erik and Brixen, Kim
Journal of bone and mineral research, ISSN 0884-0431, 04/2013, Volume 28, Issue 4, pp. 736 - 745
ZOLEDRONIC ACID | PTH 1–84 | HR‐PQCT | ANTI‐OSTEOPOROTIC TREATMENT | OSTEOPOROSIS | PTH 1–34 | HR-PQCT | PTH 1-34 | PTH 1-84 | osteoporosis | anti-osteoporotic treatment | zoledronic acid | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Bone and Bones - pathology | Radius - pathology | Humans | Middle Aged | Parathyroid Hormone - therapeutic use | Osteoporosis - drug therapy | Parathyroid Hormone - pharmacology | Tomography, X-Ray Computed | Bone Remodeling - drug effects | Tibia - pathology | Bone and Bones - drug effects | Time Factors | Bone and Bones - diagnostic imaging | Osteoporosis - diagnostic imaging | Biomechanical Phenomena - drug effects | Radius - drug effects | Aged, 80 and over | Diphosphonates - therapeutic use | Postmenopause | Female | Finite Element Analysis | Imidazoles - therapeutic use | Osteoporosis - physiopathology | Tibia - physiopathology | Biomarkers - metabolism | Radius - physiopathology | Imidazoles - pharmacology | Tibia - drug effects | Absorptiometry, Photon | Bone and Bones - physiopathology | Aged | Diphosphonates - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole
by Brufsky, Adam M and Harker, W. Graydon and Beck, J. Thaddeus and Bosserman, Linda and Vogel, Charles and Seidler, Christopher and Jin, Lixian and Warsi, Ghulam and Argonza-Aviles, Eliza and Hohneker, John and Ericson, Solveig G and Perez, Edith A
Cancer, ISSN 0008-543X, 03/2012, Volume 118, Issue 5, pp. 1192 - 1201
breast neoplasm | aromatase inhibitors | postmenopause | zoledronic acid | bone resorption | Biological and medical sciences | Medical sciences | Diseases of the osteoarticular system | Tumors of striated muscle and skeleton | Tumors | Osteoporosis, Postmenopausal - epidemiology | Bone and Bones - pathology | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Follow-Up Studies | Humans | Middle Aged | Osteoporosis, Postmenopausal - complications | Imidazoles - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Bone and Bones - drug effects | Nitriles - administration & dosage | Carcinoma - complications | Antineoplastic Agents - adverse effects | Aged, 80 and over | Diphosphonates - therapeutic use | Adult | Female | Chemotherapy, Adjuvant | Imidazoles - therapeutic use | Osteoporosis, Postmenopausal - prevention & control | Triazoles - therapeutic use | Carcinoma - drug therapy | Bone Density Conservation Agents - therapeutic use | Diphosphonates - administration & dosage | Bone Density Conservation Agents - administration & dosage | Breast Neoplasms - drug therapy | Breast Neoplasms - complications | Bone Density - drug effects | Organ Size - drug effects | Algorithms | Osteoporosis, Postmenopausal - chemically induced | Aged | Nitriles - adverse effects | Nitriles - therapeutic use | Bone resorption | Care and treatment | Usage | Menopause | Zoledronic acid | Dosage and administration | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights